Codexis Company Profile (NASDAQ:CDXS)

About Codexis

Codexis logoCodexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Industry, Sector and Symbol:
  • Sector: Industrial Products
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CDXS
  • CUSIP: 19200510
Key Metrics:
  • Previous Close: $4.50
  • 50 Day Moving Average: $4.34
  • 200 Day Moving Average: $4.03
  • 52-Week Range: $2.93 - $4.81
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -26.47
  • P/E Growth: -1.50
  • Market Cap: $185.31M
  • Outstanding Shares: 41,181,000
  • Beta: -0.75
  • Net Margins: -2.63%
  • Return on Equity: 7.82%
  • Return on Assets: 3.88%
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 2.24%
  • Quick Ratio: 2.15%
Additional Links:
Companies Related to Codexis:

Analyst Ratings

Consensus Ratings for Codexis (NASDAQ:CDXS) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (33.33% upside)

Analysts' Ratings History for Codexis (NASDAQ:CDXS)
DateFirmActionRatingPrice TargetDetails
6/1/2016HC WainwrightInitiated CoverageBuy$6.00View Rating Details
4/15/2015First AnalysisInitiated CoverageOverweightView Rating Details
3/4/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details
12/17/2014Craig HallumInitiated CoverageBuyView Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Codexis (NASDAQ:CDXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.03$0.12$15.10 million$16.00 millionViewListenView Earnings Details
5/9/2016Q1($0.15)($0.11)$7.49 million$8.00 millionViewListenView Earnings Details
3/3/2016Q4($0.04)$0.02$11.63 million$11.60 millionViewN/AView Earnings Details
11/4/2015Q315($0.11)$0.19$8.85 million$17.40 millionViewListenView Earnings Details
8/11/2015Q215($0.14)($0.14)$7.34 million$6.02 millionViewListenView Earnings Details
5/7/2015Q115($0.12)($0.14)$8.00 million$6.80 millionViewListenView Earnings Details
3/3/2015Q414$0.01$0.07$13.30 million$14.20 millionViewListenView Earnings Details
11/4/2014Q314($0.06)($0.05)$9.00 million$7.47 millionViewListenView Earnings Details
8/6/2014Q214($0.15)($0.22)$8.50 million$6.60 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.17)$10.00 million$7.10 millionViewListenView Earnings Details
3/11/2014Q413($0.21)($0.26)$10.00 million$9.50 millionViewListenView Earnings Details
11/12/2013Q313($0.31)($0.24)$8.50 million$3.90 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.28)($0.33)$9.00 million$6.97 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.36)($0.25)$7.63 million$11.48 millionViewListenView Earnings Details
2/27/2013Q4 2012($0.34)($0.41)$9.33 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.15)($0.06)$25.88 million$26.34 millionViewN/AView Earnings Details
8/9/2012($0.18)($0.15)ViewN/AView Earnings Details
5/10/2012($0.15)($0.21)ViewN/AView Earnings Details
2/7/2012($0.11)($0.15)ViewN/AView Earnings Details
11/1/2011($0.08)($0.08)ViewN/AView Earnings Details
7/28/2011($0.10)($0.14)ViewN/AView Earnings Details
5/5/2011($0.07)($0.10)ViewN/AView Earnings Details
2/3/2011($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Codexis (NASDAQ:CDXS)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.16)($0.08)($0.12)
Q2 20162$0.02$0.06$0.04
Q3 20162($0.13)($0.08)($0.11)
Q4 20162$0.05$0.06$0.06
Q1 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for Codexis (NASDAQ:CDXS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Codexis (NASDAQ:CDXS)
Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 57.24%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell111,600$4.25$474,300.00View SEC Filing  
8/29/2016Dennis P WolfDirectorSell18,000$4.22$75,960.00View SEC Filing  
8/24/2016Bernard J KelleyDirectorSell12,643$4.26$53,859.18View SEC Filing  
8/16/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell86,894$4.25$369,299.50View SEC Filing  
8/15/2016Vivo Ventures Vii, LlcMajor ShareholderSell50,000$4.27$213,500.00View SEC Filing  
8/4/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell80,000$4.22$337,600.00View SEC Filing  
11/11/2015James LalondeSVPSell9,441$3.52$33,232.32View SEC Filing  
9/11/2015Patrick Y YangDirectorBuy10,000$3.47$34,700.00View SEC Filing  
9/10/2015Bernard J. KelleyDirectorSell5,200$3.45$17,940.00View SEC Filing  
8/24/2015Patrick Y YangDirectorBuy10,000$3.84$38,400.00View SEC Filing  
8/14/2015Patrick Y YangDirectorBuy20,000$3.97$79,400.00View SEC Filing  
6/15/2015Dennis P WolfDirectorSell35,416$4.10$145,205.60View SEC Filing  
11/18/2014Patrick Y YangDirectorBuy20,000$2.35$47,000.00View SEC Filing  
11/17/2014Patrick Y YangDirectorBuy20,000$2.34$46,800.00View SEC Filing  
8/12/2014Patrick Y YangDirectorBuy60,000$2.22$133,200.00View SEC Filing  
3/8/2013John J NicolsCEOBuy27,000$2.42$65,340.00View SEC Filing  
3/7/2013John J NicolsCEOBuy54,000$2.22$119,880.00View SEC Filing  
3/4/2013David D O'tooleCFOBuy10,000$2.02$20,200.00View SEC Filing  
11/12/2012David D O'tooleCFOBuy5,000$2.20$11,000.00View SEC Filing  
9/14/2012David D O'tooleCFOBuy5,000$2.78$13,900.00View SEC Filing  
9/14/2012Douglas T SheehySVPSell3,800$2.76$10,488.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Codexis (NASDAQ:CDXS)
DateHeadline logoCODEXIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation (NASDAQ:CDXS) - October 20 at 3:38 PM
News IconBlackstone in the lead to acquire Team Health (NASDAQ:CDXS) - October 20 at 8:58 AM logoMichael Aldridge Joins Codexis as Senior Vice President, Corporate & Strategic Development (NASDAQ:CDXS) - October 17 at 9:00 AM logoCodexis, Inc. (NASDAQ:CDXS) Files An 8-K (NASDAQ:CDXS) - October 7 at 9:03 AM logoCODEXIS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CDXS) - October 5 at 4:24 PM logoCodexis Completes Transfer of CodeEvolver® Technology to Merck (NASDAQ:CDXS) - October 5 at 9:18 AM
News IconBroker Outlook For Canadian Utilities (CDUAF) (NASDAQ:CDXS) - October 4 at 4:06 PM
News IconBroker Roundup For Asanko Gold Inc. (AKG) (NASDAQ:CDXS) - October 3 at 8:56 AM logoETF’s with exposure to Codexis, Inc. : September 29, 2016 (NASDAQ:CDXS) - September 29 at 4:01 PM logoETF’s with exposure to Codexis, Inc. : September 14, 2016 (NASDAQ:CDXS) - September 14 at 4:09 PM logoCodexis to Present at September Investment Conferences (NASDAQ:CDXS) - September 6 at 8:56 AM logoHow Codexis (CDXS) Stock Stands Out in a Strong Industry (NASDAQ:CDXS) - August 18 at 12:29 PM logoCodexis, Inc. :CDXS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:CDXS) - August 15 at 4:17 PM logoEdited Transcript of CDXS earnings conference call or presentation 9-Aug-16 8:30pm GMT (NASDAQ:CDXS) - August 10 at 3:37 PM logoCodexis Reports Financial Results for the Second Quarter of 2016 (NASDAQ:CDXS) - August 9 at 9:56 PM logoCodexis beats 2Q profit forecasts (NASDAQ:CDXS) - August 9 at 9:56 PM logoQ2 2016 Codexis Inc Earnings Release - After Market Close (NASDAQ:CDXS) - August 9 at 12:47 PM logoIndustrial Stocks' Aug 9 Earnings Preview: LABL, CDXS & More (NASDAQ:CDXS) - August 8 at 8:56 AM logoCodexis Inc.: Codexis to Hold 2016 Second Quarter Conference Call on August 9 (NASDAQ:CDXS) - August 3 at 11:51 AM logoCodexis to Hold 2016 Second Quarter Conference Call on August 9 (NASDAQ:CDXS) - August 2 at 8:55 AM logoCodexis Completes Obligations Under Research and Development Agreement with Leading Biopharmaceutical Company (NASDAQ:CDXS) - July 28 at 7:08 AM logo7:01 am Codexis announces the successful completion of its obligations under a collaborative R&D agreement with a 'leading global biopharmaceutical company' (NASDAQ:CDXS) - July 28 at 7:01 AM logoETF’s with exposure to Codexis, Inc. : July 26, 2016 (NASDAQ:CDXS) - July 26 at 12:44 PM logoETF’s with exposure to Codexis, Inc. : July 1, 2016 (NASDAQ:CDXS) - July 1 at 6:02 PM logoCODEXIS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:CDXS) - June 16 at 4:04 PM logoCodexis to Present at Jefferies 2016 Healthcare Conference (NASDAQ:CDXS) - June 2 at 7:15 AM logoCodexis to Present at Upcoming Investment Conferences (NASDAQ:CDXS) - May 18 at 7:42 AM logoCodexis, Inc. :CDXS-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:CDXS) - May 17 at 2:15 PM logoEdited Transcript of CDXS earnings conference call or presentation 9-May-16 8:30pm GMT (NASDAQ:CDXS) - May 10 at 4:37 PM logoCodexis reports 1Q loss (NASDAQ:CDXS) - May 9 at 5:58 PM logoCODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:CDXS) - May 9 at 5:20 PM logoCodexis Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:CDXS) - May 9 at 4:30 PM logoCodexis Reports Financial Results for the First Quarter of 2016 (NASDAQ:CDXS) - May 9 at 4:28 PM logoQ1 2016 Codexis Inc Earnings Release - After Market Close (NASDAQ:CDXS) - May 9 at 7:07 AM logoCodexis to Hold 2016 First Quarter Conference Call on May 9 (NASDAQ:CDXS) - May 2 at 4:20 PM logoNew Broker Ratings For Codexis, Inc. (NASDAQ:CDXS) - FTSE News (NASDAQ:CDXS) - March 15 at 2:31 PM
News IconCodexis, Inc. (NASDAQ:CDXS) Updated Price Targets - Share Trading News (NASDAQ:CDXS) - March 15 at 2:31 PM logoCodexis, Inc. :CDXS-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:CDXS) - March 9 at 11:36 AM logoCODEXIS INC Files SEC form 10-K, Annual Report (NASDAQ:CDXS) - March 8 at 5:15 PM logoEdited Transcript of CDXS earnings conference call or presentation 3-Mar-16 9:30pm GMT (NASDAQ:CDXS) - March 4 at 8:20 PM logoCodexis reports 4Q loss (NASDAQ:CDXS) - March 3 at 5:34 PM logoCODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:CDXS) - March 3 at 5:07 PM logoQ4 2015 Codexis Inc Earnings Release - After Market Close (NASDAQ:CDXS) - March 3 at 7:07 AM
News IconUpdated Price Targets On Codexis, Inc. (NASDAQ:CDXS) - Risers & Fallers (NASDAQ:CDXS) - February 26 at 10:08 AM logoCodexis to Hold 2015 Fourth Quarter and Full Year Conference Call on March 3 (NASDAQ:CDXS) - February 25 at 7:00 AM logoCODEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CDXS) - February 23 at 5:22 PM logoCodexis Files Lawsuit against EnzymeWorks and CEO Junhua “Alex” Tao for Patent Infringement and Misappropriation of Trade Secrets (NASDAQ:CDXS) - February 22 at 8:21 AM
News IconCodexis Incorporated (NASDAQ:CDXS) Shorted Shares Increased By 6.85% - (NASDAQ:CDXS) - February 20 at 2:42 PM
News IconWhat's Ahead for Codexis, Inc. After Today's Huge Decline? - Sonoran Weekly Review (NASDAQ:CDXS) - February 19 at 2:56 PM
News IconCodexis Incorporated (NASDAQ:CDXS) Sellers Increased By 6.85% Their Shorts - (NASDAQ:CDXS) - February 13 at 1:58 PM


Codexis (NASDAQ:CDXS) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by Staff